Nonalcoholic fatty liver disease (NAFLD) is the most common metabolic liver disease worldwide and the burden of NAFLD is likely to increase with the epidemic of obesity and type 2 diabetes. The term NAFLD embraces a spectrum of fat-related liver conditions, that begins with steatosis (nonalcoholic fatty liver [NAFL]) and progresses to nonalcoholic steatohepatitis (NASH) with worsening fibrosis. Over time, liver fibrosis progresses, with the development of cirrhosis and increased risk of end stage liver disease.